NEWER LUNG CANCER CHEMOTHERAPY SIGNIFICANTLY MORE COSTLY THAN OLDER
Although there is statistically no difference in survival or
cancer-related quality-of-life after treatment for non-small-cell lung
cancer with carboplatin plus paclitaxel or cisplatin plus vinorelbine,
carboplatin plus paclitaxel therapy is significantly more expensive.
Reuters Health Information 2002
|Remember we are NOT Doctors and have NO medical training.|
This site is like an Encyclopedia - there are many pages, many links on many topics.
Support our work with any size DONATION - see left side of any page - for how to donate. You can help raise awareness of CAM.